| Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer K Tilekar, N Upadhyay, CV Iancu, V Pokrovsky, J Choe, CS Ramaa Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1874 (2), 188457, 2020 | 48 | 2020 |
| Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation N Upadhyay, K Tilekar, N Jänsch, M Schweipert, JD Hess, LH Macias, ... Bioorganic chemistry 100, 103934, 2020 | 36 | 2020 |
| Discovery of 5-naphthylidene-2, 4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines K Tilekar, N Upadhyay, N Jänsch, M Schweipert, P Mrowka, ... Bioorganic chemistry 95, 103522, 2020 | 36 | 2020 |
| Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy N Upadhyay, K Tilekar, F Loiodice, NY Anisimova, TS Spirina, ... Bioorganic Chemistry 107, 104527, 2021 | 30 | 2021 |
| Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential K Tilekar, N Upadhyay, JD Hess, LH Macias, P Mrowka, RJ Aguilera, ... European journal of medicinal chemistry 202, 112603, 2020 | 27 | 2020 |
| Synthesis and biological evaluation of pyrazoline and pyrrolidine‐2, 5‐dione hybrids as potential antitumor agents K Tilekar, N Upadhyay, FJ Meyer‐Almes, F Loiodice, NY Anisimova, ... ChemMedChem 15 (19), 1813-1825, 2020 | 23 | 2020 |
| Permuted 2, 4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells K Tilekar, N Upadhyay, M Schweipert, JD Hess, LH Macias, P Mrowka, ... European Journal of Pharmaceutical Sciences 154, 105512, 2020 | 22 | 2020 |
| Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects K Tilekar, JD Hess, N Upadhyay, AL Bianco, M Schweipert, A Laghezza, ... Journal of Medicinal Chemistry 64 (10), 6949-6971, 2021 | 21 | 2021 |
| Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery K Tilekar, O Shelke, N Upadhyay, A Lavecchia, CS Ramaa Journal of Molecular Structure 1250, 131767, 2022 | 16 | 2022 |
| Novel anthraquinone derivatives as dual inhibitors of topoisomerase 2 and casein kinase 2: in silico studies, synthesis and biological evaluation on leukemic cell lines A Kabir, K Tilekar, N Upadhyay, CS Ramaa Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2018 | 15 | 2018 |
| Development of 1, 2, 4-Triazole-5-Thione Derivatives as Potential Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) in Tuberculosis. D Vora, N Upadhyay, K Tilekar, V Jain, CS Ramaa Iranian Journal of Pharmaceutical Research: IJPR 18 (4), 1742, 2019 | 13 | 2019 |
| Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks N Upadhyay, K Tilekar, S Safuan, AP Kumar, M Schweipert, ... RSC Medicinal Chemistry 12 (9), 1540-1554, 2021 | 12 | 2021 |
| Double-edged swords: diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis N Upadhyay, K Tilekar, S Safuan, AP Kumar, M Schweipert, ... Bioorganic chemistry 116, 105350, 2021 | 11 | 2021 |
| Benzylidene thiazolidinediones: synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib H Joshi, V Patil, K Tilekar, N Upadhyay, V Gota, CS Ramaa Bioorganic & medicinal chemistry letters 30 (23), 127561, 2020 | 10 | 2020 |
| HDAC4 Inhibitors with Cyclic Linker and Non‐hydroxamate Zinc Binding Group: Design, Synthesis, HDAC Screening and in vitro Cytotoxicity evaluation. K Tilekar, JD Hess, N Upadhyay, M Schweipert, F Flath, DA Gutierrez, ... ChemistrySelect 6 (26), 6748-6763, 2021 | 9 | 2021 |
| Synthesis, In‐Vitro Evaluation and Molecular Docking Study of N‐Substituted Thiazolidinediones as α‐Glucosidase Inhibitors VM Patil, KN Tilekar, NM Upadhyay, CS Ramaa ChemistrySelect 7 (1), e202103848, 2022 | 8 | 2022 |
| Mechanistic insights into binding of ligands with thiazolidinedione warhead to human histone deacetylase 4 M Schweipert, N Jänsch, N Upadhyay, K Tilekar, E Wozny, S Basheer, ... Pharmaceuticals 14 (10), 1032, 2021 | 8 | 2021 |
| Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention N Upadhyay, K Tilekar, JD Hess, VS Pokrovsky, RJ Aguilera, CS Ramaa Current Research in Chemical Biology 1, 100006, 2021 | 6 | 2021 |
| Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2 N Upadhyay, K Tilekar, S Safuan, AP Kumar, M Schweipert, ... Future medicinal chemistry 13 (22), 1963-1986, 2021 | 4 | 2021 |
| Recent Anti-angiogenic Drug Discovery Efforts To Combat Cancer RCS Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, Alan P. Kumar, Jimmy ... ChemistrySelect 6, 5689 –5700, 2021 | 4 | 2021 |
